NCT03841136 is a Phase 2 clinical trial of anlotinib in Extensive-stage Small Cell Lung Cancer, sponsored by Fudan University.

Who is sponsoring NCT03841136?

NCT03841136 is sponsored by Fudan University.

What drugs are being tested in NCT03841136?

Interventions in NCT03841136: anlotinib.

What condition does NCT03841136 study?

NCT03841136 studies Extensive-stage Small Cell Lung Cancer.

Is NCT03841136 still recruiting?

NCT03841136 is currently status unknown. Last updated 28 March 2019.

Last reviewed 2019-03-28 · How we verify

NCT03841136

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

Status unknown Phase 2 Last updated 28 March 2019

What this trial tests

Phase 2 trial testing anlotinib in Extensive-stage Small Cell Lung Cancer in 70 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
1 December 2019

31 December 2021

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 April 2019
Primary completion	1 December 2019
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

anlotinib — full drug profile →

Conditions studied

Extensive-stage Small Cell Lung Cancer — all drugs for Extensive-stage Small Cell Lung Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Extensive-stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Liu C, Liao J, Wu X, Zhao X, et al · · 2022 · cited 14× · PMID 35388976 · DOI 10.1111/1759-7714.14414
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Cani M, Napoli VM, Garbo E, Ferrari G, et al · · 2023 · cited 11× · PMID 37240229 · DOI 10.3390/ijms24108883

Verify or expand the search:

Other trials of anlotinib

Trials testing the same drug.

NCT06327698 — Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line · Phase 2 · not yet recruiting
NCT06573424 — Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC · completed
NCT06354530 — A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma · Phase 2, PHASE3 · recruiting
NCT03815474 — Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients · Phase 2 · unknown

Other recruiting trials for Extensive-stage Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06479473 — Radiotherapy to All Residual Lesions After Chemoimmunotherapy · Phase 1, PHASE2 · recruiting
NCT04397003 — Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer · Phase 2 · active not recruiting
NCT04702880 — A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage · Phase 2 · active not recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03841136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 28 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03841136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing